Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10146MR)

This product GTTS-WQ10146MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10146MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6763MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ2973MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ15868MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ7521MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ13996MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ12743MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ11267MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ15081MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW